Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits.

Hahn, Cynthia K; Palmer, Adam C; Weinstock, David M

Hahn, Cynthia K; Palmer, Adam C; Weinstock, David M.

Afiliação

Hahn CK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Palmer AC; Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Weinstock DM; Merck & Co., Rahway, NJ, USA. Electronic address: david.weinstock@merck.com.

Cancer Cell ; 41(10): 1696-1698, 2023 10 09.

Article em En | MEDLINE | ID: mdl-37774696

RESUMO

Zhang et al. report a randomized phase 2 trial for diffuse large B cell lymphoma (DLBCL) that compared standard of care (R-CHOP) to R-CHOP combined with one of 5 agents matched to an individual lymphoma's genetics. Overall, the matching strategy significantly outperformed R-CHOP, laying the foundation for a paradigm-shifting phase 3 trial.

Assuntos

Linfoma Difuso de Grandes Células B; Humanos; Rituximab/uso terapêutico; Linfoma Difuso de Grandes Células B/tratamento farmacológico; Linfoma Difuso de Grandes Células B/genética; Ciclofosfamida/uso terapêutico; Vincristina/uso terapêutico; Prednisona/uso terapêutico; Doxorrubicina/uso terapêutico; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google